Harmony Biosciences Holdings Inc

NASDAQ:HRMYUnited States

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Contact Information

Headquarters

630 W Germantown Pike, Suite 215PLYMOUTH MEETING, PA, United States 19462

Phone

484-539-9800

Fax

302-655-5049

Executives

Non-Executive Chairman of the Board

Jeffrey Aronin

President, Chief Executive Officer, Director

Jeffrey Dayno

Chief Financial Officer, Chief Administrative Officer

Sandip Kapadia

Chief Scientific Officer

Kumar Budur

Chief Commercial Officer

Jeffrey Dierks